Lisa Caporelli
VP of Investor Relations
Replay available
Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call
Arbutus Biopharma Corporation (NASDAQ: ABUS) Q4 2023 earnings conference call, held 2024-02-29. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Mike McElhall
Interim President & Chief Executive Officer
Karen Sims
Chief Medical Officer
David Hastings
Chief Financial Officer
Dennis Ding
Analyst, Jefferies
Brian Scorney
Analyst, Baird
Mike Sophia
Chief Scientific Officer
Roy Buchanan
Analyst, Citizens JMP
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Arbutus Biopharma Corporation.
Replay transcript excerpt
WEBVTT 00:00:00.049 -- 00:00:05.011 Good day and thank you for standing by. Welcome to the RBDS 00:00:05.011 -- 00:00:10.232 Biopharma fourth quarter and year end 2023 financial results and corporate update 00:00:10.232 -- 00:00:15.354 conference call. At this time, all participants are in a listen only mode. 00:00:15.354 -- 00:00:19.435 After the speaker's presentation, there will be a question and answer session. 00:00:19.435 -- 00:00:24.016 To ask a question during the session, you'll need to press star 11 on your telephone 00:00:24.016 -- 00:00:28.738 and then hear an automated message advising your hand is raised. 00:00:28.738 -- 00:00:32.498 To withdraw your question, please press star 11 again. 00:00:32.498 -- 00:00:34.959 Please be advised that today's conference is being recorded. 00:00:34.959 -- 00:00:39.961 I would now like to hand the conference over to your first speaker today, Lisa 00:00:39.961 -- 00:00:45.084 Caporelli, VP of Investor Relations. Please go ahead. 00:00:45.084 -- 00:00:49.826 Thank you, Stephen. Good morning, everyone, and thank you for joining Arbutus' fourth 00:00:49.826 -- 00:00:54.988 quarter and year-end 2023 Financial Results and Corporate Update call. 00:00:54.988 -- 00:01:00.392 Joining me today from the Arbutus executive team are Mike McAhaugh, Interim 00:01:00.392 -- 00:01:03.714 President and Chief Executive Officer, Dr. 00:01:03.714 -- 00:01:08.917 Karen Sims, Chief Medical Officer, David Hastings, Chief 00:01:08.917 -- 00:01:15.300 Financial Officer, and Dr. Mike Sophia, Chief Scientific Officer. 00:01:15.361 -- 00:01:20.604 Mike McElhall will begin with a corporate update, followed by Karen, who will review 00:01:20.604 -- 00:01:25.828 our ongoing clinical programs. Dave will then provide a review of the company's 00:01:25....